News Bayer's Kerendia gets broader use in diabetic kidney disease Bayer's fast-growing Kerendia has had its label extended in the US to include chronic kidney disease associated with type 1 diabetes.
News Bayer's Kerendia on course for NHS use in heart failure Up to 280,000 people with heart failure could soon be eligible for NHS treatment with Bayer's Kerendia, following new NICE guidance.
News Bayer gets swift review for Kerendia in type 1 diabetes FDA starts a priority review of Bayer's Kerendia for chronic kidney disease in type 1 diabetes, which could end a 30-year drought in new therapies.
News Data builds behind Bayer's Kerendia in kidney disease Bayer's Kerendia has hit the spot in another phase 3 trial that could fuel its already rapid growth as a chronic kidney disease treatment.
News Bayer gets sought-after heart failure use for Kerendia Bayer's Kerendia has won FDA approval for a new heart failure indication thought to be pivotal for the product's blockbuster sales prospects.
News Bayer trial combines two top drugs for kidney disease Data from the CONFIDENCE trial shows the value of combining Bayer's Kerendia with an SGLT2 inhibitor to treat chronic kidney disease in diabetics.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.